Introduction: Denosumab reduces the risk of osteoporosis fractures in post-menopausal women. Its cost and its added therapeutic value vs. zoledronic acid justify performing an economic evaluation in the Portuguese context. A societal perspective was adopted. Methods: A Markov model simulated the risk of osteoporosis fractures (hip, vertebrae, wrist and others) across patients’ lifetime, considering their clinic...